867. Deputy Kate O'Connell asked the Minister for Health his plans or the plans of the HSE to provide or reimburse ocrelizumab for primary progressive multiple sclerosis patients in view of the decision of the UK (details supplied) [35029/19]

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy.